Compare BAFN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | PLX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 207.1M |
| IPO Year | 2021 | 1996 |
| Metric | BAFN | PLX |
|---|---|---|
| Price | $6.92 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.6K | ★ 836.2K |
| Earning Date | 10-29-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.26 | $1.65 |
| 52 Week High | $9.70 | $3.19 |
| Indicator | BAFN | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 42.44 |
| Support Level | $5.98 | $2.21 |
| Resistance Level | $6.96 | $2.75 |
| Average True Range (ATR) | 0.62 | 0.10 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 74.01 | 19.67 |
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.